![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 41, 29500-29504, October 8, 1999
From the Sp1-like transcription factors are characterized
by three highly homologous C-terminal zinc finger motifs that bind
GC-rich sequences. These proteins behave as either activators or
repressors and have begun to be classified into different subfamilies
based upon the presence of conserved motifs outside the zinc finger domain. This classification predicts that different Sp1-like
subfamilies share certain functional properties. TIEG1 and TIEG2
constitute a new subfamily of transforming growth factor- Sp1-like transcription factors have recently elicited significant
attention because of their widespread participation in the regulation
of mammalian cell homeostasis (1). Members of this family of proteins
currently include Sp1-4, BTEB1, BTEB2/IKLF, TIEG1/MGIF, TIEG2, BKLF,
EKLF, GKLF/EZF, LKLF, CPBP/Bcd, and AP2-rep, all of which are
characterized by three highly conserved C2H2 zinc finger DNA-binding domains at their C termini (2-21). Sp1-like transcription factors share over 75% similarity within these three zinc finger domains. Because of this high similarity, it is not surprising that many of these proteins bind to similar GC-rich sequences within promoters (reviewed in Ref. 1). These GC-rich sequences contribute to the regulation of a large number of genes necessary for various cellular functions, including cell proliferation, differentiation, and apoptosis (22). Thus, because of their participation in these functions, many Sp1-like proteins also function
as key regulators of morphogenesis (1).
While the DNA-binding domain of the Sp1-like transcription factor
family is highly conserved, the N-terminal regions of the proteins are
more divergent. Interestingly, it is through this domain that many of
these transcription factors regulate transcription (7, 14, 17-19,
23-30). The founding member of this family, Sp1, for example, is a
potent transcriptional activator that utilizes glutamine-rich sequences
located within its N terminus to interact with proteins from the basal
transcriptional apparatus to regulate gene expression (23). In
contrast, BKLF behaves as a transcriptional repressor through a
distinct domain within its N terminus (30). Interestingly, other
members of the Sp1-like family, such as GKLF, can behave as either a
transcriptional activator or a transcriptional repressor through two
independent regulatory domains (19). However, for several of the
Sp1-like family members, the domains responsible for transcriptional
regulation have not yet been defined.
TIEG1 is a widely expressed zinc finger transcription factor originally
identified as the product of a TGF With the goal of better understanding molecular mechanisms underlying
the function of TIEG1 and TIEG2, our laboratory has focused on defining
the structural domains used by these proteins to regulate gene
expression in mammalian cells. We and others have recently demonstrated
that the zinc finger motifs of both TIEG1 and TIEG2 bind to GC-rich
Sp1-like cis-regulatory sequences (16, 17). The functional
consequence of this interaction is the repression of promoters
containing GC-rich sequences, and at least for TIEG2, the N-terminal
region of this protein is sufficient to mediate repression (16, 17). In
the current study, we show that the N terminus of TIEG1 also mediates
repression, revealing that this region has a conserved transcriptional
function in both TIEG proteins. More importantly, using deletion and
site-directed mutagenesis together with transcriptional regulatory
assays, we have defined three independent transcriptional repression
domains conserved within TIEG proteins that we call R1, R2, and R3. R1 and R2 are 10- and 12-amino acids long, respectively, while R3 is a
longer proline-rich sequence of approximately 80 aa. Interestingly, in
contrast to several other members of the Sp1-like family, no transcriptional activation domain was found to be present in these transcription factors (7, 8, 14, 18, 19, 23-26, 28, 29). Together,
these data strongly support the biochemical similarity between TIEG1
and TIEG2 and indicate that they primarily function to silence gene
expression. Furthermore, these results expand our understanding of the
repertoire of functional domains present in Sp1-like transcription
factors for the regulation of gene expression in mammalian cells. The
importance of these results for extending the classification of
Sp1-like proteins is discussed.
Generation of GAL4 Effector Plasmids--
TIEG2-GAL4 constructs
were generated by amplifying various regions of TIEG2 by polymerase
chain reaction and cloning these in frame with the pSG424 GAL4
DBD1 effector plasmid (kindly
provided by Dr. N. J. Zeleznik-Le, University of Chicago, IL).
TIEG1 constructs were generated in the same manner. All TIEG2
constructs were numbered by amino acid using the second in-frame
methionine of the originally published sequence (the codon that best
fits the Kozak consensus translational start site) as amino acid
residue 1 (17). Site-directed proline mutagenesis of the R1 and R2
domains was performed by annealing overlapping mutant primers that span
the region of interest. Mutagenesis of the R3 domain was performed
using standard overlapping polymerase chain reaction mutagenesis. All
constructs were verified by sequencing.
GAL4-based Transcriptional Regulatory Assays--
GAL4-based
transcriptional regulatory assays were performed as described
previously (17). Briefly, 3 × 105 CHO cells were
plated in 60-mm tissue culture dishes and transfected 48 h later
with 3 µg of GAL4 effector plasmid DNA, 1 µg of
GAL45tkCAT reporter (generously provided by Dr. N. J. Zeleznik-Le), and 1 µg of pHook-LacZ (InVitrogen, Carlsbad, CA) using
LipofectAMINETM (Life Technologies, Inc.). As a control for basal
transcriptional activity, the reporter construct was co-transfected
with an effector plasmid carrying the GAL4 DNA-binding domain alone.
Co-transfection with a Gel Shift Assays--
To ascertain expression levels of each
GAL4 chimeric transcription factor used in these studies,
electromobility shift assays were performed essentially as described
previously (17, 32, 33). Briefly, concomitant with the transfection for
the GAL4-based transcriptional regulatory assay, an additional 60-mm
dish of CHO cells was co-transfected with 3 µg (or as indicated) of
each effector plasmid and 2 µg of filler DNA (pcDNA3.1+;
InVitrogen). 48 h post-transfection, cells were washed twice with
ice-cold PBS, harvested by scraping, and pelleted at 3000 × g for 5 min. Cells were then lysed in 35 µl of whole cell
extract buffer (20 mM Tris, pH 7.5, 20% glycerol, 0.5 M KCl, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 1 mM dithiothreitol), frozen at
TIEG1 and TIEG2 Act as Potent Transcriptional Repressor
Proteins--
Several studies have recently revealed the existence of
a novel subfamily of Sp1-like transcription factors, TIEG1 and TIEG2, that inhibit growth of epithelial cell populations (15, 17). These
proteins share 91% similarity within their C-terminal zinc finger
DNA-binding domain and 44% similarity within a proline-rich N
terminus. Previous biochemical studies have demonstrated that both of
these proteins bind to GC-rich sequences and repress transcription of
promoters containing these sites (16, 17). In addition, the N-terminal
region of TIEG2, when tethered to DNA through a heterologous DBD,
behaves as a potent transcriptional repression domain (17) (Fig.
1). To test whether the homologous region of TIEG1 has a similar function, in the current study, we fused the N
and C terminus of TIEG1 to the GAL4 DBD and tested its ability to
regulate a promoter carrying five GAL4 DNA-binding sites upstream of a
CAT reporter gene. Indeed, Fig. 1b demonstrates that the N-terminal regions of both TIEG1 and TIEG2 are able to repress transcription by over 95%, whereas the C-terminal regions display no
transcriptional regulatory activity. Together, these results demonstrate that the N-terminal regions of the TIEG proteins display functionally conserved transcriptional repression activity.
Deletion Mutagenesis of the N Terminus of TIEG2 Reveals the
Presence of Three Transcriptional Repressor Domains--
To identify
domains utilized by TIEG proteins to regulate transcription, we
generated a number of deletion and site-directed mutants as GAL4-TIEG
chimeric constructs. The expression and the ability of each of these
proteins to bind GAL4 DNA-binding sites was confirmed using gel shift
assays as described under "Experimental Procedures" (data not
shown). The results shown in Fig. 2
delineate three distinct domains within TIEG2, R1 (aa 24-41), R2 (aa
151-162), and R3 (aa 273-351), that repress reporter activity by at
least 75%. R1 and R2 are small peptides (17 and 12 aa, respectively), whereas R3 is a larger domain composed of approximately 80 aa (residues
273-351). Regions outside of the R1, R2, and R3 domains display no
transcriptional regulatory activity (Fig. 2b). Furthermore, smaller deletion constructs within R1 (27-34), R2 (158-160), and R3
(273-303 and 304-351) display a loss of repression activity, indicating that the domains defined using this analysis represent the
minimal functional units necessary for transcriptional repression.
Identification of Residues Critical for R1, R2, and R3 to Repress
Transcription Using Site-directed Mutagenesis--
To more precisely
define the residues responsible for the transcriptional regulatory
activity of R1, R2, and R3, we used extensive site-directed
mutagenesis. Computer-based modeling studies of the R1 domain using
SOPMA software (34) (available on the Internet) predicts that this
sequence is capable of forming an
Using a similar approach, we characterized the R2 and R3 domains of
TIEG2. Mutation of nine of the 12 residues that compose R2 did not
significantly influence repression (Fig.
4). In contrast, mutations in three
consecutive residues, Val, Ile, and Arg (aa 158-160), resulted in a
complete loss of repression activity by R2. However, these three
residues alone (GAL4-VIR) were not sufficient to repress reporter
activity. This result suggests that while the VIR peptide is essential
for R2-mediated repression, the remainder of the R2 domain also
contributes to its function.
The R3 domain of TIEG2 contains two interesting features. First, R3 is
relatively proline-rich (20%), a feature that is commonly found in
activation and repression domains (35, 36). Second, the R3 domain
contains a core sequence of approximately 20 aa (aa 311-328) that is
highly conserved (67% similar) between TIEG1 and TIEG2 (see Fig. 6).
Because of the high proline content of R3, we used serine mutants to
characterize this domain (Fig.
5a). Three of these mutants
involved changing clusters of proline residues near the beginning (aa
288-290), middle (aa 306-310), or end (aa 332-336) of this domain;
an additional mutant changed seven of the central conserved residues
(aa 317-323). As shown in Fig. 5b, all of the
proline-to-serine mutants were still able to repress transcription,
indicating that these proline residues are not essential for the
ability of R3 to repress transcription. In contrast, mutation of the
conserved core abolishes the ability of R3 to repress transcription.
Interestingly, one of the constructs used to define the R3 domain
(304-351, Fig. 2) contains this conserved sequence but is only able to
repress transcription by ~42% versus 77% for the full R3
domain. This result suggests that the central core sequence is
necessary but not sufficient for full R3-mediated repression
activity.
R1, R2, and R3 Are Conserved Repression Domains within the TIEG
Family of Transcription Factors--
An important feature of the
repression domains described above is that they share strong sequence
homology between both TIEG proteins (65, 75, and 29% similar for R1,
R2, and R3, respectively) (Fig.
6a). In addition, the central
core of R3, a region that is required for repression, is 67% similar
between TIEG1 and TIEG2. To determine whether these three domains are
functionally conserved between the TIEG proteins, we tested the ability
of the corresponding regions of TIEG1 to regulate transcription (Fig.
6b). Indeed, the R1, R2, and R3 regions of TIEG1 also
repress transcription. Furthermore, the residues that are critical for
TIEG2 repression share remarkable similarity ( Continuing with our studies on the functional characterization of
novel members of the Sp1-like family of proteins, in this report we
demonstrate that the presence of three conserved transcriptional repression domains is a defining biochemical property of TIEG proteins.
Sp1-like proteins are characterized by the presence of three highly
related C2H2 zinc finger DNA-binding motifs
(1). Currently, at least 14 different members of the Sp1-like family of
transcription factors have been shown to regulate promoters containing
GC-rich sequences (1). Interestingly, these sequences are present in
the promoters of more than 1000 different gene products (2, 22, 37,
38). Therefore, a detailed analysis of the transcriptional regulatory
properties of Sp1-like proteins will be critical for beginning to
understand the complexity of gene expression in mammalian cells.
Several laboratories are attempting to define distinct subgroups within
the growing family of Sp1-like proteins based upon the presence of
conserved regions located outside of the zinc finger motif. We and
others have recently reported that this classification can help to
predict biochemical and functional properties of novel proteins that
are being added to this family of transcription factors (reviewed in
Ref. 1). In addition, these studies are providing useful information
for understanding whether different members of the Sp1-like family of
proteins display distinct or redundant functions. The Sp1-like
subgroups that have been identified thus far include the SP (Sp1, Sp2,
Sp3, and Sp4), BTEB (BTEB1 and BTEB2), KLF (EKLF, GKLF, and LKLF), CPBP
(CPBP, Zf9, and UKLF), and TIEG (TIEG1 and TIEG2) proteins. The
SP proteins contain glutamine-rich N-terminal transcriptional
activation domains, the BTEB proteins activate transcription through a
hydrophobic-rich domain, and the CPBP proteins encode an acidic
activation domain (14, 18, 26, 28, 39). The KLF proteins are defined by
the presence of two different types of conserved sequences that act as
a nuclear localization signal and a putative proline-rich
transcriptional regulatory domain, respectively (8, 19, 24, 40). As
demonstrated in this study, the TIEG proteins are defined by the
presence of three conserved sequences that act as transcriptional
repressors. Thus, together this information suggests that different
subfamilies of Sp1-like proteins have evolved to mediate distinct
transcriptional functions.
Understanding the structure and function of distinct transcriptional
regulatory motifs within transcription factor proteins constitutes an
active field of research that has been helpful for understanding the
control of gene expression. For instance, several activation domains
have been recently identified on the basis of their amino acid
compositions, including glutamine-, proline-, serine/threonine-, and
acidic residue-rich domains (35, 38). Other activation domains,
however, have recently been defined that do not fall into these
categories, suggesting that a diverse array of domains can activate
transcription. Emerging evidence indicates that many activation domains
interact with specific co-activator proteins to regulate the basal
transcriptional machinery or chromatin structure to increase
transcription initiation. For example, the glutamine-rich regions of
Sp1 activate transcription by binding to TAFII130 to
recruit the RNA polymerase II-associated preinitiation complex to
target promoters, while the proline-rich activation domain of EKLF
specifically recruits E-RC1, a SWI-SNF chromatin remodeling complex, to
allow transcriptional activation to occur (41-43). Therefore,
different activation domains can initiate transcription through
interactions with distinct co-activator proteins.
Although far less understood than transcriptional activation,
repression is also crucial for the regulation of gene expression and
morphogenesis. Over the past few years, several distinct
transcriptional repression domains have been identified in eukaryotic
transcription factors (36, 44). Like activation domains, these domains
can be loosely classified into families based on amino acid
composition. Some repression domains, for example, are charged,
hydrophobic, alanine-, or proline-rich, whereas others are unique in
amino acid composition. In addition, repression domains can range in size from as little as four amino acids to hundreds of amino acids long. The short peptide sequence WRP(W/Y) found in the Hairy and Runt
families of transcriptional repressors, for example, is sufficient to
repress transcription through interaction with members of the Groucho
family of transcriptional co-repressors (45). In contrast, other
repressor proteins, such as the thyroid hormone receptor, require the
cooperative use of three large, less well defined, hydrophilic and
hydrophobic regions in order to achieve full repressive activity (46).
Similar to the WRP(W/Y) motif, the R1, R2, and core of the R3 domain of
TIEG1 and TIEG2 are short amino acid sequences necessary for repression
and are well conserved among family members. These results suggest a
conserved mechanism for regulating transcription for TIEG proteins. It
is therefore likely that the conserved repression domains of TIEG1 and
TIEG2 are used to contact either one or more co-repressor molecules.
Noteworthy, however, is that all three of the repression domains
identified in this study represent novel sequences, sharing no specific
homology with other regulatory domains. Because of the novelty of these sequences, it is difficult to speculate as to the identity of these
co-repressor proteins. Therefore, identification of potential R1, R2,
and R3 interacting proteins and the detailed characterization of these
interactions will further increase our understanding of the mechanisms
underlying TIEG-mediated transcriptional repression in mammalian cells.
Three novel transcriptional repressor domains are a defining
feature of the TIEG subfamily of Sp1-like proteins. The presence of
these domains suggest that, in contrast to other Sp1-like proteins, the
TIEG subfamily has evolved to silence gene expression in mammalian cells. These results, together with previous studies from other laboratories, are being used to generate a structural and functional classification of the growing family of Sp1-like zinc finger proteins. This classification will be useful for predicting common as well as
distinct biochemical and functional properties of members of this family.
We thank Karen Hedin and Vijay Shaw for
critically reviewing the manuscript.
*
This work was supported by the Mayo Cancer Center and
National Institutes of Health (NIH) Grant DK52913 (to R. U.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
These authors contributed equally to this work.
¶
Supported by NIH Training Grant DK07198.
The abbreviations used are:
DBD, DNA-binding
domain;
CAT, chloramphenicol acetyltransferase;
CHO, Chinese hamster
ovary;
aa, amino acid(s).
Three Conserved Transcriptional Repressor Domains Are a Defining
Feature of the TIEG Subfamily of Sp1-like Zinc Finger Proteins*
§¶,
,
,
, and
**
Gastroenterology Research Unit,
Department of Molecular Neurosciences, and ** Department of
Biochemistry and Molecular Biology, Mayo Clinic,
Rochester, Minnesota 55901
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES
-inducible
Sp1-like proteins whose zinc finger motifs also bind GC-rich sequences. However, regions outside of the DNA-binding domain that differ in
structure from other Sp1-like family members remain poorly characterized. Here, we have used extensive mutagenesis and GAL4-based transcriptional assays to identify three repression domains within TIEG1 and TIEG2 that we call R1, R2, and R3. R1 is 10 amino acids, R2
is 12 amino acids, and R3 is approximately 80 amino acids long. None of
these domains share homology with previously described transcriptional
regulatory motifs, but they share strong sequence homology and are
functionally conserved between TIEG1 and TIEG2. Together, these data
demonstrate that TIEG proteins are capable of repressing transcription,
define domains critical for this function, and further support the idea
that different subfamilies of Sp1-like proteins have evolved to mediate
distinct transcriptional functions.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES
-inducible gene from osteoblastic
cell populations (10). Studies from our laboratory have revealed that
TIEG1 is a novel member of the Sp1-like family of transcription factors
that inhibits the growth of epithelial cell populations (15).
Subsequent studies from other laboratories have demonstrated that the
inhibitory effect of TIEG1 on cell growth is also observed in
mesenchymal cells (31). Moreover, recent reports have shown that TIEG1
is a target of glial cell-derived neurotrophic factor-mediated
signaling in neuronal cells (16). Thus, TIEG1 appears to be part of the
molecular machinery that regulates the growth of cells from various
lineages. As the result of a search for novel Sp1-like transcription
factors, we have recently identified TIEG2, a protein structurally
related to TIEG1 (17). These two proteins are 91% similar within the
C-terminal DNA-binding domain and 44% similar throughout their N
termini. Like TIEG1, TIEG2 is inducible by TGF
signaling and
inhibits epithelial cell growth. Thus, based upon their sequence
similarity, TGF
inducibility, and effect on epithelial cell
proliferation, we have proposed that TIEG1 and TIEG2 form a distinct
subgroup of Sp1-like transcription factors (17).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES
-galactosidase expression plasmid, pHook-LacZ
(Promega), was performed to control for transfection efficiency.
Relative CAT activity was assayed using an enzyme-linked immunosorbent assay method from Roche Molecular Biochemicals, and
-galactosidase activity was measured using the
-galactosidase enzyme assay system (Promega). In all experiments, CAT activity was determined using the
same amount of protein (50 µg), and the values were normalized to
-galactosidase activity. Studies were performed in triplicate in at
least three independent experiments with similar results.
80 °C, and thawed at 4 °C. Cellular debris and unlysed cells
were pelleted at 10,000 × g for 10 min at 4 °C, and
lysates were transferred to fresh tubes. Protein concentrations were
assayed using the BCA method (Pierce). 10 µg of whole cell extracts
was incubated 10 min at room temperature in a buffer containing 4%
glycerol, 1 mM MgCl2, 0.5 mM EDTA,
0.5 mM dithiothreitol, 50 mM NaCl, 10 mM Tris-HCl, pH 7.5, and 50 µg/ml
poly(dI-dC)·poly(dI-dC) (Promega, Madison, WI). A double-stranded
GAL4 DNA-binding site, 5'-GGAGTACTGTCCTCCGAG-3' was end-labeled with
[
-32P]ATP with T4 polynucleotide kinase according to
the manufacturer's suggestions (Promega, Madison, WI). 0.35 pmol of
end-labeled GAL4 probe was then added to each reaction for an
additional 20 min, and the reactions were loaded immediately onto a 4%
nondenaturing polyacrylamide gel. Samples were run for 3 h at 120 V at room temperature, vacuum-dried, and exposed to X-Omat film
(Eastman Kodak Co.) at room temperature.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES

View larger version (27K):
[in a new window]
Fig. 1.
TIEG1 and TIEG2 contain a potent
transcriptional repression domain within their N termini.
a, chimeric cDNAs were generated by cloning the N or C
terminus of TIEG1 and TIEG2 in frame with the DNA-binding domain of the
yeast transcription factor GAL4 (GAL4 DBD). b, these
constructs were tested for the ability to regulate transcription of the
CAT reporter gene driven by a promoter carrying five GAL4 DNA-binding
sites. Assays were performed in CHO cells. Bars, S.D. Note
that the N-terminal region of both TIEG1 and TIEG2 strongly represses
transcription compared with the DBD alone, while the C-terminal regions
have no transcriptional regulatory effect.

View larger version (23K):
[in a new window]
Fig. 2.
Mapping of the transcriptional regulatory
domains within TIEG2. Various portions of the N-terminal
region of TIEG2 were tested in the GAL4 transcriptional regulatory
assay described in Fig. 1. a, lines indicate the
position of the construct tested compared with the N terminus of TIEG2;
corresponding amino acids are listed to the left; and the
average percentage of CAT expression compared with expression by the
GAL4 DBD alone (100%) is listed to the right. b,
histogram representing the relative CAT expression for constructs
spanning the regions between or the regions encoding the R1, R2, and R3
domains. These domains were defined as the minimal sequences tested
that provide transcriptional regulatory activity greater than 3-fold
over control. Bars, S.D.
-helical structure. Therefore, we
generated sequential mutations along the R1 domain of TIEG2 using the
helix-breaking proline residue as a mutagen (Fig.
3a). We then tested each of
these mutants for their ability to maintain transcriptional repression.
As shown in Fig. 3, mutations within the central core of the R1 domain, corresponding to amino acid residues 30-39 (AVEALVCMSS), resulted in a
complete loss of transcriptional regulatory activity, while mutations
outside of this core did not abolish repression. Additional results
demonstrate that this decapeptide is also sufficient to repress
transcription. Therefore, these results define a 10-aa core sequence
that is required for the R1 domain to function.

View larger version (24K):
[in a new window]
Fig. 3.
Mapping of the residues involved in
R1-mediated repression. a, consecutive mutations within
the R1 domain of TIEG2 were generated by replacing each amino acid
residue with a proline. These mutant R1 domains were then tested in a
GAL4 assay (b). Mutations 5-14, corresponding to the amino
acid sequence AVEALCMSS, were unable to repress reporter activity more
than 2-fold, while mutations outside this region could still support
transcriptional repression. Furthermore, a construct encoding the
residues mapped using proline mutagenesis, AVEALVCMSS, is sufficient to
repress transcription. Bars, S.D.

View larger version (17K):
[in a new window]
Fig. 4.
Mapping of the residues involved in
R2-mediated repression. Scanning proline mutations were generated
to span the entire R2 domain of TIEG2 (a). These mutant GAL4
DBD chimeric effector plasmids were then tested for their ability to
regulate transcription (b). Note that only mutations in
residues VIR (constructs 8-10) lose the ability to repress
transcription. However, a GAL4 DBD-VIR (VIR) construct is not
sufficient to repress transcription.

View larger version (12K):
[in a new window]
Fig. 5.
Mapping of the residues involved in
R3-mediated repression. a, four serine-based mutants
were generated in the R3 domain of TIEG2. Mutants 1, 2, and 4 mutate
prolines to serines, while mutant 3 changes a core of residues present
within a conserved region between TIEG1 and TIEG2 (shaded).
These mutant GAL4 DBD chimeric effector plasmids were tested for their
ability to regulate transcription (b). Note that mutations
in the proline residues do not affect the ability of the R3 domain to
repress transcription (1, 2, 4), while a mutation of the conserved
region alleviates transcriptional repression (3).
80%) between both TIEG
proteins (Figs. 3-6). Interestingly, the data presented in Figs. 2 and
6 also suggested that the R1, R2, and R3 domains exhibit different levels of repressor activity. To assess their differential strengths, we compared dose-response curves for R1, R2, and R3 from TIEG2. From
these experiments, we find that all three domains display repression
activity in a dose-dependent manner. However, the R1, R2,
and R3 domains exhibit different relative strengths: 92, 84, and 51%
repression, respectively, at the highest dose tested. For this
comparison, gel shift analysis of each GAL4-TIEG2 chimeric protein was
performed to determine equal DNA binding activity (Fig.
7b). Together, these results
reveal that the three distinct transcriptional repressor domains are
not only structurally conserved but are also functionally conserved
within the TIEG subfamily of Sp1-like proteins.

View larger version (17K):
[in a new window]
Fig. 6.
R1, R2, and R3 are conserved in TIEG1 and
TIEG2. a, sequence comparisons of the R1, R2, and R3
domains of TIEG2 (from Fig. 2) compared with TIEG1 show a remarkable
conservation between these regions. The R1 domain is 65% similar, the
R2 domain is 75% similar, and the R3 domain is 29% similar.
Dark gray indicates identical residues, and
light gray indicates similar residues. Proline
residues in the R3 domain are boxed, and a core of ~20 aa
in the R3 domain that is 67% similar between TIEG2 and TIEG1 is marked
with asterisks. No other homology was detected with other
proteins using existing data bases. b, histogram
representing relative CAT expression from GAL4-TIEG1 constructs
carrying the putative R1, R2, and R3 domains. Bars, S.D.
Note that in addition to being homologous, each of these domains is
functionally conserved between TIEG1 and TIEG2.

View larger version (27K):
[in a new window]
Fig. 7.
Dose-dependent repression
activity of R1, R2, and R3. a, GAL4-based
transcriptional regulatory assay using increasing amounts of effector
plasmids (DBD and R1: 0.25, 0.5, 1, and 2 µg; R2 and R3: 0.0375, 0.075, 0.15, and 0.3 µg). Effector and reporter plasmids were
transfected in CHO cells and analyzed for relative CAT expression as
described under "Experimental Procedures." Bars, S.D.
Note that in all cases, a dose-dependent repression is
observed, and under all conditions, the R1 domain most effectively
represses transcription. b, CHO cells were transfected with
2 µg of the GAL4-DBD, 2 µg of R1, 0.3 µg of R2, or 0.3 µg of R3
effector plasmid. pcDNA3.1+ plasmid was added to each transfection
to reach a total of 5 µg, and transfections were performed
concomitantly with the experiment in a as described under
"Experimental Procedures." 10 µg of whole cell lysates from each
sample were then used in a gel shift assay using the GAL4 DNA-binding
site as a probe. The asterisk indicates a degradation
product. This experiment was performed three times with identical
results.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES
![]()
CONCLUSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES

To whom correspondence should be addressed: GI Research Unit,
Saint Mary's Hospital, Mayo Clinic, Rochester, MN 55905. Tel.: 507-284-7500; Fax: 507-255-6318; E-mail: urrutia.raul@mayo.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
CONCLUSION
REFERENCES
1.
Cook, T.,
Gebelein, B.,
and Urrutia, R.
(1999)
Ann. N. Y. Acad. Sci.
880,
94-102[CrossRef][Medline]
[Order article via Infotrieve]
2.
Kadonaga, J. T.,
Carner, K. R.,
Masiarz, F. R.,
and Tjian, R.
(1987)
Cell
51,
1079-1090[CrossRef][Medline]
[Order article via Infotrieve]
3.
Hagen, G.,
Muller, S.,
Beato, M.,
and Suske, G.
(1992)
Nucleic Acids Res.
20,
5519-5525 4.
Imataka, H.,
Sogawa, K.,
Yasumoto, K.,
Kikuchi, Y.,
Sasano, K.,
Kobayashi, A.,
Hayami, M.,
and Fujii-Kuriyama, Y.
(1992)
EMBO J.
11,
3663-3671[Medline]
[Order article via Infotrieve]
5.
Kingsley, C.,
and Winoto, A.
(1992)
Mol. Cell. Biol.
12,
4251-4261 6.
Miller, I. J.,
and Bieker, J. J.
(1993)
Mol. Cell. Biol.
13,
2776-2786 7.
Sogawa, K.,
Imataka, H.,
Yamasaki, Y.,
Kusume, H.,
Abe, H.,
and Fujii-Kuriyama, Y.
(1993)
Nucleic Acids Res.
21,
1527-1532 8.
Anderson, K. P.,
Kern, C. B.,
Crable, S. C.,
and Lingrel, J. B.
(1995)
Mol. Cell. Biol.
15,
5957-5965[Abstract]
9.
Blok, L. J.,
Grossmann, M. E.,
Perry, J. E.,
and Tindall, D. J.
(1995)
Mol. Endocrinol.
9,
1610-1620[Abstract]
10.
Subramaniam, M.,
Harris, S. A.,
Oursler, M. J.,
Rasmussen, K.,
Riggs, B. L.,
and Spelsberg, T. C.
(1995)
Nucleic Acids Res.
23,
4907-4912 11.
Crossley, M.,
Whitelaw, E.,
Perkins, A.,
Williams, G.,
Fujiwara, Y.,
and Orkin, S. H.
(1996)
Mol. Cell. Biol.
16,
1695-1705[Abstract]
12.
El Rouby, S.,
and Newcomb, E. W.
(1996)
Oncogene
13,
2623-2630[Medline]
[Order article via Infotrieve]
13.
Shields, J. M.,
Christy, R. J.,
and Yang, V. W.
(1996)
J. Biol. Chem.
271,
20009-20017 14.
Koritschoner, N. P.,
Bocco, J. L.,
Panzetta-Dutari, G. M.,
Dumur, C. I.,
Flury, A.,
and Patrito, L. C.
(1997)
J. Biol. Chem.
272,
9573-9580 15.
Tachibana, I.,
Imoto, M.,
Adjei, P.,
Gores, G. J.,
Subramaniam, M.,
Spelsberg, T. C.,
and R., U.
(1997)
J. Clin. Invest.
99,
2365-2374[Medline]
[Order article via Infotrieve]
16.
Yajima, S.,
Lammers, C. H.,
Lee, S. H.,
Hara, Y.,
Mizuno, K.,
and Mouradian, M. M.
(1997)
J. Neurosci.
17,
8657-8666 17.
Cook, T.,
Gebelein, B.,
Mesa, K.,
Mladek, A.,
and Urrutia, R.
(1998)
J. Biol. Chem.
273,
25929-25936 18.
Matsumoto, N.,
Laub, F.,
Aldabe, R.,
Zhang, W.,
Ramirez, F.,
Yoshida, T.,
and Terada, M.
(1998)
J. Biol. Chem.
273,
28229-28237 19.
Yet, S. F.,
McA'Nulty, M. M.,
Folta, S. C.,
Yen, H. W.,
Yoshizumi, M.,
Hsieh, C. M.,
Layne, M. D.,
Chin, M. T.,
Wang, H.,
Perrella, M. A.,
Jain, M. K.,
and Lee, M. E.
(1998)
J. Biol. Chem.
273,
1026-1031 20.
Imhof, A.,
Schuierer, M.,
Werner, O.,
Moser, M.,
Roth, C.,
Bauer, R.,
and Buettner, R.
(1999)
Mol. Cell. Biol.
19,
194-204 21.
Conkright, M. D.,
Wani, M. A.,
Anderson, K. P.,
and Lingrel, J. B.
(1999)
Nucleic Acids Res.
27,
1263-1270 22.
Liu, C.,
Calogero, A.,
Ragona, G.,
Adamson, E.,
and Mercola, D.
(1996)
Crit. Rev. Oncogenesis
7,
101-125[Medline]
[Order article via Infotrieve]
23.
Courey, A. J.,
and Tjian, R.
(1988)
Cell
55,
887-898[CrossRef][Medline]
[Order article via Infotrieve]
24.
Bieker, J. J.,
and Southwood, C. M.
(1995)
Mol. Cell. Biol.
15,
852-860[Abstract]
25.
Hagen, G.,
Dennig, J.,
Preiß, A.,
Beato, M.,
and Suske, G.
(1995)
J. Biol. Chem.
270,
24989-24994 26.
Kobayashi, A.,
Sogawa, K.,
Imataka, H.,
and Fujii-Kuriyama, Y.
(1995)
J. Biochem. (Tokyo)
117,
91-95 27.
Dennig, J.,
Beato, M.,
and Suske, G.
(1996)
EMBO J.
15,
5659-5667[Medline]
[Order article via Infotrieve]
28.
Kojima, S.,
Kobayashi, A.,
Gotoh, O.,
Ohkuma, Y.,
Fujii-Kuriyama, Y.,
and Sogawa, K.
(1997)
J. Biochem. (Tokyo)
121,
389-396 29.
Majello, B.,
De Luca, P.,
and Lania, L.
(1997)
J. Biol. Chem.
272,
4021-4026 30.
Turner, J.,
and Crossley, M.
(1998)
EMBO J.
17,
5129-5140[CrossRef][Medline]
[Order article via Infotrieve]
31.
Tau, K. R.,
Hefferan, T. E.,
Waters, K. M.,
Robinson, J. A.,
Subramaniam, M.,
Riggs, B. L.,
and Spelsberg, T. C.
(1998)
Endocrinology
139,
1346-1353 32.
Alevizopoulos, A.,
and Mermod, N.
(1996)
J. Biol. Chem.
271,
29672-29681 33.
Martinez, E.,
Dusserre, Y.,
Wahli, W.,
and Mermod, N.
(1991)
Mol. Cell. Biol.
11,
2937-2945 34.
Geourjon, C.,
and Deleage, G.
(1995)
Comp. Appl. Biosci.
11,
681-684 35.
Triezenberg, S. J.
(1995)
Curr. Opin. Genet. Dev.
5,
190-196[CrossRef][Medline]
[Order article via Infotrieve]
36.
Hanna-Rose, W.,
and Hansen, U.
(1996)
Trends Genet.
12,
229-234[CrossRef][Medline]
[Order article via Infotrieve]
37.
Dynan, W. S.,
and Tjian, R.
(1985)
Nature
316,
774-778[CrossRef][Medline]
[Order article via Infotrieve]
38.
Mitchell, P. J.,
and Tjian, R.
(1989)
Science
245,
371-378 39.
Lania, L.,
Majello, B.,
and De Luca, P.
(1997)
Intl. J. Biochem. Cell Biol.
29,
1313-1323[CrossRef][Medline]
[Order article via Infotrieve]
40.
Shields, J. M.,
and Yang, V. W.
(1997)
J. Biol. Chem.
272,
18504-18507 41.
Gill, G.,
Pascal, E.,
Tseng, Z. H.,
and Tjian, R.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
192-196 42.
Tanese, N.,
Saluja, D.,
Vassallo, M. F.,
Chen, J. L.,
and Admon, A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
13611-13616 43.
Armstrong, J. A.,
Bieker, J. J.,
and Emerson, B. M.
(1998)
Cell
95,
93-104[CrossRef][Medline]
[Order article via Infotrieve]
44.
Gray, S.,
and Levine, M.
(1996)
Curr. Opin. Cell Biol.
8,
358-364[CrossRef][Medline]
[Order article via Infotrieve]
45.
Fisher, A. L.,
and Caudy, M.
(1998)
Genes Dev.
12,
1931-1940 46.
Busch, K.,
Martin, B.,
Baniahmad, A.,
Renkawitz, R.,
and Muller, M.
(1997)
Mol. Endocrinol.
11,
379-389
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
R. Alvarez-Rodriguez, M. Barzi, J. Berenguer, and S. Pons Bone Morphogenetic Protein 2 Opposes Shh-mediated Proliferation in Cerebellar Granule Cells through a TIEG-1-based Regulation of Nmyc J. Biol. Chem., December 21, 2007; 282(51): 37170 - 37180. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Fujimura, T. Vacik, O. Machon, C. Vlcek, S. Scalabrin, M. Speth, D. Diep, S. Krauss, and Z. Kozmik Wnt-mediated Down-regulation of Sp1 Target Genes by a Transcriptional Repressor Sp5 J. Biol. Chem., January 12, 2007; 282(2): 1225 - 1237. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-Q. Liu, S. Tan, M. C. Mendel, R. J. Murrills, B. M. Bhat, B. Schlag, R. Samuel, J. J. Matteo, R. de la Rosa, K. Howes, et al. Isogenic Human Cell Lines for Drug Discovery: Regulation of Target Gene Expression by Engineered Zinc-Finger Protein Transcription Factors J Biomol Screen, June 1, 2005; 10(4): 304 - 313. [Abstract] [PDF] |
||||
![]() |
M. Subramaniam, G. Gorny, S. A. Johnsen, D. G. Monroe, G. L. Evans, D. G. Fraser, D. J. Rickard, K. Rasmussen, J. M. A. van Deursen, R. T. Turner, et al. TIEG1 Null Mouse-Derived Osteoblasts Are Defective in Mineralization and in Support of Osteoclast Differentiation In Vitro Mol. Cell. Biol., February 1, 2005; 25(3): 1191 - 1199. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Cao, M. E. Fernandez-Zapico, D. Jin, V. Puri, T. A. Cook, L. O. Lerman, X.-Y. Zhu, R. Urrutia, and V. Shah KLF11-mediated Repression Antagonizes Sp1/Sterol-responsive Element-binding protein-induced Transcriptional Activation of Caveolin-1 in Response to Cholesterol Signaling J. Biol. Chem., January 21, 2005; 280(3): 1901 - 1910. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ganss and A. Jheon ZINC FINGER TRANSCRIPTION FACTORS IN SKELETAL DEVELOPMENT Crit. Rev. Oral. Biol. Med., September 1, 2004; 15(5): 282 - 297. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Noti, A. K. Johnson, and J. D. Dillon The Zinc Finger Transcription Factor Transforming Growth Factor {beta}-Inducible Early Gene-1 Confers Myeloid-specific Activation of the Leukocyte Integrin CD11d Promoter J. Biol. Chem., June 25, 2004; 279(26): 26948 - 26958. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-M. Ou, K. Chen, and J. C. Shih Dual Functions of Transcription Factors, Transforming Growth Factor-{beta}-inducible Early Gene (TIEG)2 and Sp3, Are Mediated by CACCC Element and Sp1 Sites of Human Monoamine Oxidase (MAO) B Gene J. Biol. Chem., May 14, 2004; 279(20): 21021 - 21028. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Tomlinson, J. C. Grindley, and A. A. Thomson Regulation of Fgf10 Gene Expression in the Prostate: Identification of Transforming Growth Factor-{beta}1 and Promoter Elements Endocrinology, April 1, 2004; 145(4): 1988 - 1995. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Abbud, R. Kelleher, and S. Melmed Cell-Specific Pituitary Gene Expression Profiles after Treatment with Leukemia Inhibitory Factor Reveal Novel Modulators for Proopiomelanocortin Expression Endocrinology, February 1, 2004; 145(2): 867 - 880. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Rabbani, K. Maruyama, H. Abe, M. A. Khan, K. Katsura, Y. Ito, K. Yoshiwara, M. Seki, K. Shinozaki, and K. Yamaguchi-Shinozaki Monitoring Expression Profiles of Rice Genes under Cold, Drought, and High-Salinity Stresses and Abscisic Acid Application Using cDNA Microarray and RNA Gel-Blot Analyses Plant Physiology, December 1, 2003; 133(4): 1755 - 1767. [Abstract] [Full Text] |
||||
![]() |
S. A. Johnsen, M. Subramaniam, D. G. Monroe, R. Janknecht, and T. C. Spelsberg Modulation of Transforming Growth Factor beta (TGFbeta )/Smad Transcriptional Responses through Targeted Degradation of TGFbeta -inducible Early Gene-1 by Human Seven in Absentia Homologue J. Biol. Chem., August 16, 2002; 277(34): 30754 - 30759. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Zhang, M. C. Moncrieffe, J. Kaczynski, V. Ellenrieder, F. G. Prendergast, and R. Urrutia A Conserved {alpha}-Helical Motif Mediates the Interaction of Sp1-Like Transcriptional Repressors with the Corepressor mSin3A Mol. Cell. Biol., August 1, 2001; 21(15): 5041 - 5049. [Abstract] [Full Text] [PDF] |
||||